我们在论文"丰富的有意义的先导药物:深度对抗式自编码器在肿瘤学中新分子开发的应用"中描述了使用对抗式自编码器(AAE)生成新分子的概念,该论文于2016年6月提交至Oncotarget杂志发表。Alan Aspuru-Guzik团队在他们的ArXiv论文"利用数据驱动持续分子表示的自动化学设计"(Automatic chemical design)中发表了类似的想法。在此期间,我们开始合作,并围绕生成化学搭建了一个全球社区。
Dr. Charles Cantor Professor Emeritus at Boston University, Co-Founder of Sequenom Inc., Co-Founder of Retrotope Inc. Former Principal Scientist of Human Genome Project, Department of Energy, Co-founder of Sequenom (acquired by LabCorp), Professor and Director of the Center for Advanced Biotechnology, Boston University
Dr. Tudor Oprea Professor and Chief, Translational Informatics Division, The University of New Mexico One of the top experts in target discovery with 25+ years in the industry Built IDG-KMC, TCRD, Pharos, and Drug Central target discovery tools and organizations H-index = 72
Dr. Yuan-Hua Ding Founder & CEO at ATB Former VP & Head of Pfizer Asia Discovery Lab Drug discovery expert with over 20 years of experience in structural biology
Dr. Alán Aspuru-Guzik Professor of Chemistry and Computer Science, University of Toronto Expert in Quantum Computing, Quantum Chemistry, Machine Learning Professor, Harvard, Department of Chemistry 2006-2018 H-index = 82
Dr. Yuri Nikolsky CEO, MiLaboratories CEO, Sybille BioSciences Co-founder of GeneGo (acquired by Thomson Reuters) Former VP of Life Sciences, Thomson Reuters Developer of MetaCore, MetaBase and other tools for target discovery H-index = 48
Dr. Stevan Djuric Expert in Drug Discovery and Development Former VP of Abbvie and Abbott Laboratories Over 30 years experience in Medicinal Chemistry and Immunoinflammatory disease Adjunct professor at The University of Kansas, High Point University H-index > 30
Dr. Jeremy Levin Chairman and CEO, Ovid Therapeutics Inc Chairman of the Biotechnology Innovation Organization (BIO)